Thermodilution - Controlled Management of Volume Therapy in Septic Shock (THEMIS)

This study is currently recruiting participants.
Verified October 2013 by Charite University, Berlin, Germany
Sponsor:
Information provided by (Responsible Party):
Claudia Spies, Charite University, Berlin, Germany
ClinicalTrials.gov Identifier:
NCT01263977
First received: December 20, 2010
Last updated: October 17, 2013
Last verified: October 2013

December 20, 2010
October 17, 2013
December 2010
July 2014   (final data collection date for primary outcome measure)
Duration of septic shock [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
septic shock is defined as sepsis with mean arterial pressure (MAP) <65mmHg or systolic arterial pressure (SAP) <90mmHg or the need for vasopressors to support the MAP >/= 65 mmHg or the SAP >/= 90 mmHg
Same as current
Complete list of historical versions of study NCT01263977 on ClinicalTrials.gov Archive Site
  • 28 day mortality [ Time Frame: max 28 Tage ] [ Designated as safety issue: No ]
  • 90 and 180 days mortality [ Time Frame: max 180 days ] [ Designated as safety issue: No ]
  • Intensive care mortality [ Time Frame: max 28 days ] [ Designated as safety issue: No ]
  • Frequency of arterial hypoperfusion in the extremity of the thermodilution [ Time Frame: max. 28 days ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Thermodilution - Controlled Management of Volume Therapy in Septic Shock
A Randomized Mono-center Study Looking at the Effect of Thermodilution Controlled Therapy for Volume Optimization on the Duration of Septic Shock in Patients With Septic Shock

Septic shock and multi-organ failure are among the most frequent causes of death in the ICU.

Patients with septic shock require early implementation of hemodynamic therapy to keep the duration of shock state and with it microcirculatory disturbances as short as possible. In the septic shock guidelines by the american association SCCM the diagnosis of volume status is based on filling pressures, like CVP. Some studies show, that the CVP depends not only on the intravascular volume, but also on the right ventricular compliance, pulmonary vascular resistance as well as intrathoracic pressure. The aim of the Study is to evaluate if the duration of septic shock can be reduced through algorithm driven volume therapy orientated to thermodilution based volume parameters (GEDI and ELWI)

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Septic Shock
  • Volume Status
Device: Picco- thermodilution catheter
Transpulmonary thermodilution and pulse contour analysis with arterial catheter Arterial access via femoral
  • Experimental: Thermodilution controlled volume management
    Volume management based on parameters: GEDI, ELWI, CI
    Intervention: Device: Picco- thermodilution catheter
  • Active Comparator: Volume management based on surviving sepsis campaign
    volume management based on surviving sepsis campaign guidelines: CVP, Urin output, MAP, ScvO2
    Intervention: Device: Picco- thermodilution catheter
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
December 2014
July 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Informed consent from patient, authorized proxy, carer
  • In women of child bearing age, effective contraceptive use with a known failure rate of <1 %
  • Clinical verification of infection (≥ 48 hours possible), with at least one criteria from a - d required:

    1. Proof of pathological microorganism in blood, sputum, urine or normally sterile body tissues
    2. Identifiable focus (e.g. purulent sputum or wound secretion, perforated gut)
    3. Identification of granulocytes in normally sterile tissue
    4. Clinical suspicion of infection without identification of pathogens or micro-organisms (e.g. new pulmonary infiltrates on chest x-ray, treated pneumonia, purpura fulminants, necrotizing fasciitis)
  • Confirmation of SIRS (≥ 48 hours possible), with at least 2 criteria from a-d required:

    1. Fever (≥38 °C) or Hypothermia (≤ 36 °C)
    2. Tachycardia (≥ 90/min)
    3. Tachypnoea (≥ 20/min) or Hyperventilation (PaCO2 ≤ 32 mmHg, ≤ 4,4 kPa) or mechanical ventilation
    4. Leukocytes (≥ 12,000/μl) or Leucopenia (≤ 4,000/μl) or ≥ 10% immature granulocytes
  • Sepsis-induced HYPOTENSION despite adequate volume status (<24h):

Mean arterial pressure (MAP) < 65 mmHg (< 8,7 kPa) or systolic arterial pressure (SAP) < 90 mmHg (< 12 kPa) or the need for vasopressor (Norepinephrine <0.05µg/kg/min) to support the MAP ≥ 65 mmHg (≥ 8,7 kPa) or the SAP ≥ 90 mmHg ≥ 12 kPa), when one of these criteria has lasted for 4 hours or longer.

Exclusion Criteria:

  • Therapy limited (DNR-Order)
  • Patient moribund
  • Pregnancy (positive pregnancy test in women of child bearing age)
  • Breast feeding women
  • Age < 18 years
  • Patients active treatment for congestive heart failure with Ejection fraction < 30% and/or NYHA Class IV congestive heart failure
  • Severe peripheral Arterial Vascular Occlusion Disease ≥ 2b after Fontaine
  • Patients with Glasgow Coma Score ≤ 8 at the time of admission and prior to the administration of medications such as sedatives
  • Patients with TNM stage 4 solid tumors, hematologic malignancies with high tumor burden, CNS tumors (WHO stage 4)
  • Patients who are likely to die within days for diseases or conditions other than catecholamine-dependent shock
  • Participation in another interventional clinical study within the last 30 days
  • Particular relationship to senior investigator (e.g. staff, relative, colleague)
  • Patients with severe liver dysfunction (Child C)
  • Patients with septic shock within the last 60 days
  • Patients receiving norepinephrine for longer than 48 hours
Both
18 Years and older
No
Contact: Michael Sander, MD +4930450531 ext 012 Michael.Sander@charite.de
Contact: Marit Habicher, MD +49 30 450 531 ext 052 Marit.Habicher@charite.de
Germany
 
NCT01263977
THEMIS
No
Claudia Spies, Charite University, Berlin, Germany
Claudia Spies
Not Provided
Study Director: Claudia D Spies, MD, Prof. Dept. of Anesthesiology and Intensive Care Medicine, CCM and CVK, Charité - Universitaetsmedizin Berlin
Principal Investigator: Michael Sander, MD, Prof. Dept. of Anesthesiology and Intensive Care Medicine, CCM and CVK, Charité - Universitaetsmedizin Berlin
Charite University, Berlin, Germany
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP